| Todd Jeffrey Garvin, MD | |
|
9398 Ridgetop Blvd Nw, Silverdale, WA 98383-8505 | |
| (360) 782-3222 | |
| (360) 782-3245 |
| Full Name | Todd Jeffrey Garvin |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 44 Years |
| Location | 9398 Ridgetop Blvd Nw, Silverdale, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538111836 | NPI | - | NPPES |
| 4038840 | Other | AETNA | |
| 340006217 | Other | RAILROAD MEDICARE | |
| 78764 | Other | WA | LABOR & INDUSTRIES |
| GA9641 | Other | REGENCE BLUE SHIELD | |
| 8139636 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD00029847 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harrison Medical Center | Bremerton, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
News Archive
The Globe and Mail examines the sustainability of Sierra Leone's free health care system, writing, "The reform has been hugely successful and the death rate has dropped sharply. ... But the country's hospitals are overwhelmed with new patients, the drug supply can't keep up, the medical staff are overloaded, and it's unclear if the $36-million program would survive without foreign donations."
Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.
The Society for Women's Health Research gathered three lung cancer experts on Capitol Hill on September 17, 2007 to inform Congress on the need for increased funding to research lung cancer and its impact on women.
Results from a Spanish study suggest that the prevalence of obsessive‑compulsive disorder and associated symptoms among children is higher than previously thought.
An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.
› Verified 5 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
The Globe and Mail examines the sustainability of Sierra Leone's free health care system, writing, "The reform has been hugely successful and the death rate has dropped sharply. ... But the country's hospitals are overwhelmed with new patients, the drug supply can't keep up, the medical staff are overloaded, and it's unclear if the $36-million program would survive without foreign donations."
Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.
The Society for Women's Health Research gathered three lung cancer experts on Capitol Hill on September 17, 2007 to inform Congress on the need for increased funding to research lung cancer and its impact on women.
Results from a Spanish study suggest that the prevalence of obsessive‑compulsive disorder and associated symptoms among children is higher than previously thought.
An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Todd Jeffrey Garvin, MD 9621 Ridgetop Blvd Nw, Silverdale, WA 98383-8502 Ph: (360) 782-3200 | Todd Jeffrey Garvin, MD 9398 Ridgetop Blvd Nw, Silverdale, WA 98383-8505 Ph: (360) 782-3222 |
News Archive
The Globe and Mail examines the sustainability of Sierra Leone's free health care system, writing, "The reform has been hugely successful and the death rate has dropped sharply. ... But the country's hospitals are overwhelmed with new patients, the drug supply can't keep up, the medical staff are overloaded, and it's unclear if the $36-million program would survive without foreign donations."
Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.
The Society for Women's Health Research gathered three lung cancer experts on Capitol Hill on September 17, 2007 to inform Congress on the need for increased funding to research lung cancer and its impact on women.
Results from a Spanish study suggest that the prevalence of obsessive‑compulsive disorder and associated symptoms among children is higher than previously thought.
An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.
› Verified 5 days ago
Dr. Jason Michael Durbin, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3222 Fax: 360-782-3244 | |
Theodore Eugene Johnsrude, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3200 Fax: 360-782-3245 | |
Dr. Marc A Mitchell, DO Urology Medicare: Accepting Medicare Assignments Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3222 Fax: 360-782-3245 | |
Amy Li, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3200 Fax: 360-782-3244 | |
Randall James Moeller, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3200 Fax: 360-782-3244 | |
Marc E. Lee, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 10452 Silverdale Way Nw, Silverdale, WA 98383 Phone: 360-307-7300 |